Author:
Choueiri Toni K,Escudier Bernard,Powles Thomas,Tannir Nizar M,Mainwaring Paul N,Rini Brian I,Hammers Hans J,Donskov Frede,Roth Bruce J,Peltola Katriina,Lee Jae Lyun,Heng Daniel Y C,Schmidinger Manuela,Agarwal Neeraj,Sternberg Cora N,McDermott David F,Aftab Dana T,Hessel Colin,Scheffold Christian,Schwab Gisela,Hutson Thomas E,Pal Sumanta,Motzer Robert J
Reference29 articles.
1. Kidney cancer, version 3. 2015;Motzer;J Natl Compr Canc Netw,2015
2. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy;Powles;Eur Urol,2016
3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
4. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol Cancer Ther,2011
5. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma;Gibney;Ann Oncol,2013
Cited by
818 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献